<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LANOXIN- digoxinÂ tabletÂ </strong><br>Cardinal Health<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use LANOXIN safely and effectively. See full prescribing information for LANOXIN. <br><br>LANOXIN<span class="Sup">Â®</span> (digoxin) tablets, for oral use<br>Initial U.S. Approval: 1954</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">LANOXIN is a cardiac glycoside indicated for: </p>
<dl>
<dt>â€¢</dt>
<dd>Treatment of mild to moderate <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> in adults. (<a href="#i4i_section_id_41eaacc6-3cda-4409-9aec-dfdbf1ee345d">1.1</a>)</dd>
<dt>â€¢</dt>
<dd>Increasing myocardial contractility in pediatric patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. (<a href="#i4i_section_id_4611eab7-0d6a-4dd2-a4ad-085982552c08">1.2</a>)</dd>
<dt>â€¢</dt>
<dd>Control of resting ventricular rate in patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">chronic atrial fibrillation</span> in adults. (<a href="#i4i_section_id_7fda3845-c27c-4053-80eb-bc14be4bce0a">1.3</a>)</dd>
</dl>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">LANOXIN dose is based on patient-specific factors (age, lean body weight, renal function, etc.). See full prescribing information. Monitor for toxicity and therapeutic effect. (<a href="#i4i_dosage_admin_id_fdb0cad7-dcff-452a-8d2f-feaafee383c1">2</a>)  </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Unscored Tablets:  62.5 and 187.5 mcg.  Scored Tablets 125 and 250 mcg (<a href="#i4i_dosage_form_strength_id_ccaa12e1-fe36-4327-ac91-a64c3043d1b0">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">Ventricular fibrillation</span>. (<a href="#i4i_contraindications_id_080284df-78ee-4cfc-bd1c-f00c68ab5318">4</a>)</dd>
<dt>â€¢</dt>
<dd>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to digoxin or other forms of digitalis. (<a href="#i4i_contraindications_id_080284df-78ee-4cfc-bd1c-f00c68ab5318">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Risk of rapid ventricular response leading to <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> in patients with AV accessory pathway. (<a href="#i4i_section_id_e63ec79f-822f-4a6a-8412-67e38be76bb8">5.1</a>)</dd>
<dt>â€¢</dt>
<dd>Risk of advanced or <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">complete heart block</span> in patients with sinus node disease and <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>. (<a href="#i4i_section_id_866f103f-78b6-4c51-882b-7e94d5c74cf3">5.2</a>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Digoxin toxicity</span>: Indicated by <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>. Advanced age, low body weight, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> and electrolyte abnormalities predispose to toxicity. (<a href="#i4i_section_id_f205b362-6aef-4293-b00d-ff36c4f56536">5.3</a>)</dd>
<dt>â€¢</dt>
<dd>Risk of <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> during electrical cardioversion. (<a href="#ID_de7202af-caa6-4e9b-8874-2c13b4ca059e">5.4</a>)</dd>
<dt>â€¢</dt>
<dd>Not recommended in patients with <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>. (<a href="#i4i_section_id_a442e88d-f067-416c-a0ef-ff37c4fc16e1">5.5</a>)</dd>
<dt>â€¢</dt>
<dd>Avoid LANOXIN in patients with <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>. (<a href="#i4i_section_id_1f6f5128-3644-4e62-ae50-13c598344f51">5.6</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The overall incidence of adverse reactions with digoxin has been reported as 5-20%, with 15-20% of adverse events considered serious. Cardiac toxicity accounts for about one-half, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> for about one-fourth, and CNS and other toxicity for about one-fourth of these adverse events. (<a href="#i4i_section_id_99f6a114-4476-4814-8122-937998ecd4c9">6.1</a>) <br><br> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Covis Pharmaceuticals, Inc at 1-866-488-4423 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>.</span> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>PGP Inducers/Inhibitors: Drugs that induce or inhibit PGP have the potential to alter digoxin pharmacokinetics. (<a href="#i4i_section_id_4394fdb7-2435-4f1d-b4e7-1ae9b1e4acfc">7.1</a>)</dd>
<dt>â€¢</dt>
<dd>Many drug interactions. The potential for drug-drug interactions must be considered prior to and during drug therapy. See full prescribing information. (<a href="#i4i_section_id_281cc437-7c81-478b-b7f7-91bcbae4ff98">7.3</a>, <a href="#i4i_pharmacokinetics_id_3e1e0190-dd10-42a4-a02b-1d0e6d8dac15">12.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Pregnant patients: It is unknown whether use during pregnancy can cause fetal harm. (<a href="#i4i_pregnancy_id_5ce90afc-2f1e-45e1-be10-c935e8f18824">8.1</a>)</dd>
<dt>â€¢</dt>
<dd>Pediatric patients: Newborn infants display variability in tolerance to LANOXIN. (<a href="#i4i_pediatric_use_id_e712826b-1db0-4c21-8a8b-408a55cc6e26">8.4</a>)</dd>
<dt>â€¢</dt>
<dd>Geriatric patients: Consider renal function in dosage selection, and carefully monitor for side effects. (<a href="#i4i_geriatric_use_id_f80a0adf-1994-4c4f-b6c2-8c6c9a14576b">8.5</a>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>: LANOXIN is excreted by the kidneys. Consider renal function during dosage selection. (<a href="#i4i_section_id_eb9bb812-458c-49d5-a474-cbda03b4a949">8.6</a>)</dd>
</dl></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 9/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> in Adults</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> in Pediatric Patients</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span> in Adults</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Important Dosing and Administration Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Loading Dosing Regimen in Adults and Pediatric Patients</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Maintenance Dosing in Adults and Pediatric Patients Over 10 Years Old</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Maintenance Dosing in Pediatric Patients Less Than 10 Years Old</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Monitoring to Assess Safety, Efficacy, and Therapeutic Blood Levels</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Switching from Intravenous Digoxin to Oral Digoxin</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">Ventricular Fibrillation</span> in Patients With Accessory AV Pathway (Wolff-Parkinson-White Syndrome)</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus Bradycardia</span> and Sino-atrial Block</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Digoxin Toxicity</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Risk of <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular Arrhythmias</span> During Electrical Cardioversion</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Risk of <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">Ischemia</span> in Patients With <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span> </a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">Vasoconstriction</span> In Patients With <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Decreased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">Cardiac Output</span> in Patients With Preserved Left Ventricular Systolic Function</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Reduced Efficacy In Patients With <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Altered Response in <span class="product-label-link" type="condition" conceptid="141253" conceptname="Disorder of thyroid gland">Thyroid Disorders</span> and Hypermetabolic States</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 P-Glycoprotein (PGP) Inducers/Inhibitors</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Pharmacokinetic Drug Interactions</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Potentially Significant Pharmacodynamic Drug Interactions</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Drug/Laboratory Test Interactions</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.8" class="toc">8.8 <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">Malabsorption</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-9.1" class="toc">10.1 Signs and Symptoms in Adults and Children</a></h2>
<h2><a href="#section-9.2" class="toc">10.2 Treatment</a></h2>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Chronic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2 <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Chronic Atrial Fibrillation</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_cd4bb30a-cf05-478d-a508-50a204bcd17b"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_41eaacc6-3cda-4409-9aec-dfdbf1ee345d"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> in Adults</h2>
<p class="First">LANOXIN is indicated for the treatment of mild to moderate <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> in adults. LANOXIN increases left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> and improves <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> symptoms as evidenced by improved exercise capacity and decreased <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>-related hospitalizations and emergency care, while having no effect on mortality. Where possible, LANOXIN should be used in combination with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4611eab7-0d6a-4dd2-a4ad-085982552c08"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> in Pediatric Patients</h2>
<p class="First">Digoxin increases myocardial contractility in pediatric patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7fda3845-c27c-4053-80eb-bc14be4bce0a"></a><a name="section-1.3"></a><p></p>
<h2>1.3 <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span> in Adults</h2>
<p class="First">LANOXIN is indicated for the control of ventricular response rate in adult patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">chronic atrial fibrillation</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_fdb0cad7-dcff-452a-8d2f-feaafee383c1"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_75d31293-0976-48df-8999-c40e338fcbc9"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Important Dosing and Administration Information</h2>
<p class="First">In selecting a LANOXIN dosing regimen, it is important to consider factors that affect digoxin blood levels (e.g., body weight, age, renal function, concomitant drugs) since toxic levels of digoxin are only slightly higher than therapeutic levels.  Dosing can be either initiated with a loading dose followed by maintenance dosing if rapid titration is desired <span class="Bold">or</span> initiated with maintenance dosing without a loading dose.</p>
<p>Consider interruption or reduction in LANOXIN digoxin dose prior to electrical cardioversion <span class="Italics">[see Warnings and Precautions (<a href="#ID_de7202af-caa6-4e9b-8874-2c13b4ca059e">5.4</a>)].</span></p>
<p>Use digoxin solution to obtain the appropriate dose in infants, young pediatric patients, or patients with very low body weight. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dfa0a6b6-ec6d-4a9d-b30e-0f685237797b"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Loading Dosing Regimen in Adults and Pediatric Patients</h2>
<p class="First">For adults and pediatric patients if a loading dosage is to be given, administer half the total loading dose initially, then Â¼ the loading dose every 6-8 hours twice, with careful assessment of clinical response and toxicity before each dose. The recommended loading dose is displayed in <a href="#_Ref370203024">Table 1</a>.</p>
<a name="_Ref370203024"></a><table width="100%">
<caption><span>Table 1. Recommended LANOXIN Oral Loading Dose</span></caption>
<col width="45%">
<col width="50%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="2" valign="top">mcg = microgram</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Age</span></p></td>
<td class="Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Â Â Â Â Â TotalÂ OralÂ LoadingÂ DoseÂ (mcg/kg)Â Â Â Â Â </span></p>
<p>Administer half the total loading dose initially, <br>then Â¼ the loading dose every 6 to 8 hours twice</p>
</td>
</tr>
<tr>
<td valign="top"><p class="First">5 to 10 years</p></td>
<td align="center" valign="top"><p class="First">20-45</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">AdultsÂ andÂ pediatricÂ patientsÂ overÂ 10Â yearsÂ Â Â Â Â </p></td>
<td class="Botrule" align="center" valign="top"><p class="First">10-15</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ddbda300-49f7-4e82-88c3-80fc831e8771"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Maintenance Dosing in Adults and Pediatric Patients Over 10 Years Old</h2>
<p class="First">The maintenance dose is based on lean body weight, renal function, age, and concomitant products <span class="Italics">[see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_3e1e0190-dd10-42a4-a02b-1d0e6d8dac15">12.3</a>)]</span>. </p>
<p>The recommended <span class="Bold">starting</span> maintenance dose in adults and pediatric patients over 10 years old with normal renal function is given in <a href="#_Ref370203087">Table 2</a>. Doses may be increased every 2Â weeks according to clinical response, serum drug levels, and toxicity.</p>
<a name="_Ref370203087"></a><table width="100%">
<caption><span>Table 2. Recommended Starting LANOXIN Maintenance Dosage in Adults and Pediatric Patients Over 10 Years Old</span></caption>
<col width="45%">
<col width="50%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="2" valign="top">mcg = microgram</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Age</span></p></td>
<td class="Toprule" align="center" valign="top"><p class="First"><span class="Bold">Â Â Â Â Â Total OralÂ MaintenanceÂ Dose,Â mcg/kg/dayÂ Â Â Â Â </span><br><span class="Bold">(given once daily)</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">AdultsÂ andÂ pediatricÂ patientsÂ overÂ 10Â yearsÂ Â Â Â Â </p></td>
<td class="Botrule" align="center" valign="top"><p class="First">3.4-5.1</p></td>
</tr>
</tbody>
</table>
<p><a href="#_Ref370203148">Table 3</a> provides the recommended (once daily) maintenance dose for adults and pediatric patients over 10 years old (to be given once daily) according to lean body weight and renal function. The doses are based on studies in adult patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.  Alternatively, the maintenance dose may be estimated by the following formula (peak body stores lost each day through elimination):</p>
<p>Total Maintenance Dose = Loading Dose (i.e., Peak Body Stores) x % Daily Loss/100<br>(% Daily Loss = 14 + Creatinine clearance/5)</p>
<p>Reduce the dose of LANOXIN in patients whose lean weight is an abnormally small fraction of their total body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> because of <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. </p>
<a name="_Ref370203148"></a><table width="100%">
<caption><span>Table 3. Recommended Maintenance Dose (in micrograms given once daily) of LANOXIN in Pediatric Patients Over 10 Years Old and Adults by Lean Body Weight and by Renal Function<span class="Sup">a</span></span></caption>
<col width="12%">
<col width="4%">
<col width="11%">
<col width="11%">
<col width="11%">
<col width="11%">
<col width="11%">
<col width="11%">
<col width="11%">
<col width="9%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="12" valign="top">
<span class="Sup">a</span>Â Â Doses are rounded to the nearest dose possible using whole LANOXIN tablets. Recommended doses approximately 30 percent lower than the calculated dose are designated with an *.  Monitor digoxin levels in patients receiving these initial doses and increase dose if needed.<br><span class="Sup">b</span>Â Â <span class="Italics">For adults</span>, creatinine clearance was corrected to 70-kg body weight or 1.73 m<span class="Sup">2</span> body surface area.  If only serum creatinine concentrations (Scr) are available, a corrected Ccr may be estimated in men as (140 â€“ Age)/Scr. For women, this result should be multiplied by 0.85.<br><span class="Italics">For pediatric</span> patients, the modified Schwartz equation may be used. The formula is based on height in cm and Scr in mg/dL where k is a constant. Ccr is corrected to 1.73 m<span class="Sup">2</span> body surface area. During the first year of life, the value of k is 0.33 for pre-term babies and 0.45 for term infants. The k is 0.55 for pediatric patients and adolescent girls and 0.7 for adolescent boys.<br>GFR (mL/min/1.73 m<span class="Sup">2</span>) = (k x Height)/Scr<br><span class="Sup">c</span>Â Â If no loading dose administered.<br><span class="Sup">d</span>Â Â The doses listed assume average body composition.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" rowspan="2" valign="middle"><p class="First"><span class="Bold">Corrected </span><br><span class="Bold">Creatinine </span><br><span class="Bold">Clearance<span class="Sup">b</span></span></p></td>
<td class="Toprule" align="center" colspan="8" valign="middle"><p class="First"><span class="Bold">Lean Body Weight<span class="Sup">d</span></span></p></td>
<td class="Toprule" rowspan="2" valign="middle"><p class="First"><span class="Bold">Number of Days </span><br><span class="Bold">Before Steady </span><br><span class="Bold">State Achieved<span class="Sup">c</span></span></p></td>
</tr>
<tr>
<td align="center" valign="middle"><p class="First"><span class="Bold">kg</span></p></td>
<td align="center" valign="middle"><p class="First"><span class="Bold">40</span></p></td>
<td align="center" valign="middle"><p class="First"><span class="Bold">50</span></p></td>
<td align="center" valign="middle"><p class="First"><span class="Bold">60</span></p></td>
<td align="center" valign="middle"><p class="First"><span class="Bold">70</span></p></td>
<td align="center" valign="middle"><p class="First"><span class="Bold">80</span></p></td>
<td align="center" valign="middle"><p class="First"><span class="Bold">90</span></p></td>
<td align="center" valign="middle"><p class="First"><span class="Bold">100</span></p></td>
</tr>
<tr>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>10 mL/min</dd>
</dl></td>
<td valign="middle"></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>62.5*</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>250</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>19</dd>
</dl></td>
</tr>
<tr>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>20 mL/min</dd>
</dl></td>
<td valign="middle"></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>250</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>250</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>16</dd>
</dl></td>
</tr>
<tr>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>30 mL/min</dd>
</dl></td>
<td valign="middle"></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>250</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>250</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>312.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>14</dd>
</dl></td>
</tr>
<tr>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>40 mL/min</dd>
</dl></td>
<td valign="middle"></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>250</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>250</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>312.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>312.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>13</dd>
</dl></td>
</tr>
<tr>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>50 mL/min</dd>
</dl></td>
<td valign="middle"></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>250</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>250</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>312.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>312.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>12</dd>
</dl></td>
</tr>
<tr>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>60 mL/min</dd>
</dl></td>
<td valign="middle"></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>250</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>250</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>312.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>312.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>375</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>11</dd>
</dl></td>
</tr>
<tr>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>70 mL/min</dd>
</dl></td>
<td valign="middle"></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>250</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>250</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>312.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>375</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>375</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>10</dd>
</dl></td>
</tr>
<tr>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>80 mL/min</dd>
</dl></td>
<td valign="middle"></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>250</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>312.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>312.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>375</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>437.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>9</dd>
</dl></td>
</tr>
<tr>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>90 mL/min</dd>
</dl></td>
<td valign="middle"></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>250</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>250</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>312.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>375</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>437.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>437.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>8</dd>
</dl></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="middle"><dl>
<dt>Â </dt>
<dd>100 mL/min</dd>
</dl></td>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td class="Botrule" valign="middle"><dl>
<dt>Â </dt>
<dd>250</dd>
</dl></td>
<td class="Botrule" valign="middle"><dl>
<dt>Â </dt>
<dd>312.5</dd>
</dl></td>
<td class="Botrule" valign="middle"><dl>
<dt>Â </dt>
<dd>312.5</dd>
</dl></td>
<td class="Botrule" valign="middle"><dl>
<dt>Â </dt>
<dd>375</dd>
</dl></td>
<td class="Botrule" valign="middle"><dl>
<dt>Â </dt>
<dd>437.5</dd>
</dl></td>
<td class="Botrule" valign="middle"><dl>
<dt>Â </dt>
<dd>500</dd>
</dl></td>
<td class="Botrule" valign="middle"><dl>
<dt>Â </dt>
<dd>7</dd>
</dl></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4c2ed626-280f-4b7f-85d7-3a68ebea2056"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Maintenance Dosing in Pediatric Patients Less Than 10 Years Old</h2>
<p class="First">The starting maintenance dose for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> in pediatric patients less than 10 years old is based on lean body weight, renal function, age, and concomitant products <span class="Italics">[see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_3e1e0190-dd10-42a4-a02b-1d0e6d8dac15">12.3</a>)]</span>.  The recommended <span class="Bold">starting</span> maintenance dose for pediatric patients between 5 years and 10 years old is given in <a href="#_Ref370205955">Table 4</a>. These recommendations assume the presence of normal renal function.  </p>
<a name="_Ref370205955"></a><table width="100%">
<caption><span>Table 4. Recommended Starting LANOXIN Oral Maintenance Dosage in Pediatric Patients between 5 and 10 Years Old</span></caption>
<col width="43%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="top"><p class="First"><span class="Bold">Age</span></p></td>
<td class="Toprule" align="center" valign="top"><p class="First"><span class="Bold">Oral Maintenance Dose,</span><br><span class="Bold">mcg/kg/dose</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">5Â yearsÂ toÂ 10Â years</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">3.2-6.4Â Â Â <span class="Bold">TwiceÂ daily</span></p></td>
</tr>
</tbody>
</table>
<p><a href="#_Ref370212092">Table 5</a> provides average daily maintenance dose requirements for pediatric patients between 5 and 10 years old (to be given twice daily) with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> based on age, lean body weight, and renal function.</p>
<a name="_Ref370212092"></a><table width="100%">
<caption><span>Table 5. Recommended Maintenance Dose (in micrograms given TWICE daily) of LANOXIN in Pediatric Patients between 5 and 10 Years of Age<span class="Sup">a</span> Based upon Lean Body Weight and Renal Function<span class="Sup">a,b</span></span></caption>
<col width="15%">
<col width="7%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="13%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="10" valign="top">
<span class="Sup">a</span>Â Â Recommended are doses to be given twice daily.<br><span class="Sup">b</span>Â Â The doses are rounded to the nearest dose possible using whole LANOXIN tablets. Recommended doses approximately 30 percent lower than the calculated dose are designated with an *. Monitor digoxin levels in patients receiving these initial doses and increase dose if needed.<br><span class="Sup">c</span>Â Â The modified Schwartz equation may be used to estimate creatinine clearance.  See footnote b under <a href="#_Ref370203148">Table 3</a>.<br><span class="Sup">d</span>Â Â If no loading dose administered.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" rowspan="2" valign="middle"><p class="First"><span class="Bold">Corrected</span><br><span class="Bold">Creatinine</span><br><span class="Bold">Clearance<span class="Sup">c</span></span></p></td>
<td class="Toprule" align="center" colspan="6" valign="middle"><p class="First"><span class="Bold">Lean Body Weight</span></p></td>
<td class="Toprule" rowspan="2" valign="middle"><p class="First"><span class="Bold">Number of Days</span><br><span class="Bold">Before Steady</span><br><span class="Bold">State Achieved<span class="Sup">d</span></span></p></td>
</tr>
<tr>
<td align="center" valign="middle"><p class="First"><span class="Bold">kg</span></p></td>
<td align="center" valign="middle"><p class="First"><span class="Bold">20</span></p></td>
<td align="center" valign="middle"><p class="First"><span class="Bold">30</span></p></td>
<td align="center" valign="middle"><p class="First"><span class="Bold">40</span></p></td>
<td align="center" valign="middle"><p class="First"><span class="Bold">50</span></p></td>
<td align="center" valign="middle"><p class="First"><span class="Bold">60</span></p></td>
</tr>
<tr>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>10 mL/min</dd>
</dl></td>
<td valign="middle"></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>-</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>62.5</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>62.5*</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>19</dd>
</dl></td>
</tr>
<tr>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>20 mL/min</dd>
</dl></td>
<td valign="middle"></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>62.5</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>62.5</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>16</dd>
</dl></td>
</tr>
<tr>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>30 mL/min</dd>
</dl></td>
<td valign="middle"></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>62.5</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>62.5*</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>14</dd>
</dl></td>
</tr>
<tr>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>40 mL/min</dd>
</dl></td>
<td valign="middle"></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>62.5</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>62.5*</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>13</dd>
</dl></td>
</tr>
<tr>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>50 mL/min</dd>
</dl></td>
<td valign="middle"></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>62.5</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>12</dd>
</dl></td>
</tr>
<tr>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>60 mL/min</dd>
</dl></td>
<td valign="middle"></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>62.5</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>250</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>11</dd>
</dl></td>
</tr>
<tr>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>70 mL/min</dd>
</dl></td>
<td valign="middle"></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>62.5</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>250</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>10</dd>
</dl></td>
</tr>
<tr>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>80 mL/min</dd>
</dl></td>
<td valign="middle"></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>62.5*</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>250</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>9</dd>
</dl></td>
</tr>
<tr>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>90 mL/min</dd>
</dl></td>
<td valign="middle"></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>62.5*</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>250</dd>
</dl></td>
<td valign="bottom"><dl>
<dt>Â </dt>
<dd>250</dd>
</dl></td>
<td valign="middle"><dl>
<dt>Â </dt>
<dd>8</dd>
</dl></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="middle"><dl>
<dt>Â </dt>
<dd>100 mL/min</dd>
</dl></td>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="bottom"><dl>
<dt>Â </dt>
<dd>62.5*</dd>
</dl></td>
<td class="Botrule" valign="bottom"><dl>
<dt>Â </dt>
<dd>125</dd>
</dl></td>
<td class="Botrule" valign="bottom"><dl>
<dt>Â </dt>
<dd>187.5</dd>
</dl></td>
<td class="Botrule" valign="bottom"><dl>
<dt>Â </dt>
<dd>250</dd>
</dl></td>
<td class="Botrule" valign="bottom"><dl>
<dt>Â </dt>
<dd>312.5</dd>
</dl></td>
<td class="Botrule" valign="middle"><dl>
<dt>Â </dt>
<dd>7</dd>
</dl></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bf18b8a3-beb9-4adf-82bd-17727e091d65"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Monitoring to Assess Safety, Efficacy, and Therapeutic Blood Levels</h2>
<p class="First">Monitor for signs and symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> and clinical response.  Adjust dose based on toxicity, efficacy, and blood levels.</p>
<p>Serum digoxin levels less than 0.5 ng/mL have been associated with diminished efficacy, while levels above 2 ng/mL have been associated with increased toxicity without increased benefit.  </p>
<p>Interpret the serum digoxin concentration in the overall clinical context, and do not use an isolated measurement of serum digoxin concentration as the basis for increasing or decreasing the LANOXIN dose. Serum digoxin concentrations may be falsely elevated by endogenous digoxin-like substances <span class="Italics">[see Drug Interactions (<a href="#i4i_section_id_6fed24c4-0844-4365-81e6-3ea33fce8e0e">7.4</a>)]</span>. If the assay is sensitive to these substances, consider obtaining a baseline digoxin level before starting LANOXIN and correct post-treatment values by the reported baseline level. </p>
<p>Obtain serum digoxin concentrations just before the next scheduled LANOXIN dose or at least 6Â hours after the last dose. The digoxin concentration is likely to be 10-25% lower when sampled right before the next dose (24 hours after dosing) compared to sampling 8 hours after dosing (using once-daily dosing). However, there will be only minor differences in digoxin concentrations using twice daily dosing whether sampling is done at 8 or 12Â hours after a dose. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_142a1a90-3f30-4872-94f1-598bd749a504"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Switching from Intravenous Digoxin to Oral Digoxin</h2>
<p class="First">When switching from intravenous to oral digoxin formulations, make allowances for differences in bioavailability when calculating maintenance dosages (see <a href="#_Ref370212923">Table 6</a>).</p>
<a name="_Ref370212923"></a><table width="100%">
<caption><span>Table 6. Comparison of the Systemic Availability and Equivalent Doses of Oral and Intravenous LANOXIN</span></caption>
<col width="35%">
<col width="20%">
<col width="11%">
<col width="11%">
<col width="11%">
<col width="11%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"></td>
<td class="Toprule" align="center" valign="top"><p class="First"><span class="Bold">Absolute</span><br><span class="Bold">Â Â Â BioavailabilityÂ Â Â </span></p></td>
<td class="Toprule" align="center" colspan="4" valign="top"><p class="First"><span class="Bold">Â Â Â EquivalentÂ DosesÂ (mcg)Â Â Â </span></p></td>
</tr>
<tr>
<td valign="top"><p class="First">LANOXIN Tablets</p></td>
<td align="center" valign="top"><p class="First">60-80%</p></td>
<td align="center" valign="top"><p class="First">Â Â Â 62.5Â Â Â </p></td>
<td align="center" valign="top"><p class="First">125</p></td>
<td align="center" valign="top"><p class="First">250</p></td>
<td align="center" valign="top"><p class="First">500</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">LANOXINÂ IntravenousÂ InjectionÂ Â Â </p></td>
<td class="Botrule" align="center" valign="top"><p class="First">100%</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">50</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">Â Â Â 100Â Â Â </p></td>
<td class="Botrule" align="center" valign="top"><p class="First">Â Â Â 200Â Â Â </p></td>
<td class="Botrule" align="center" valign="top"><p class="First">Â Â Â 400Â Â Â </p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_ccaa12e1-fe36-4327-ac91-a64c3043d1b0"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Unscored Tablets: 62.5 mcg are peach, round with â€œU3Aâ€? imprinted on one side.<br>Scored Tablets: 125 mcg are yellow, round, scored tablets with â€œY3Bâ€? imprinted on one side.<br>Unscored Tablets: 187.5 mcg are blue, round with â€œF3Fâ€? imprinted on one side.<br>Scored Tablets: 250 mcg are white, round, scored tablets with â€œX3Aâ€? imprinted on one side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_080284df-78ee-4cfc-bd1c-f00c68ab5318"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">LANOXIN is contraindicated in patients with:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">Ventricular fibrillation</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_e63ec79f-822f-4a6a-8412-67e38be76bb8">5.1</a>)]</span>
</dd>
<dt>â€¢</dt>
<dd>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to digoxin (reactions seen include unexplained <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the mouth, lips or throat or a difficulty in breathing). A <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to other digitalis preparations usually constitutes a contraindication to digoxin.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_d3853e2c-c99a-4eef-b8a5-6d3308004dc0"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e63ec79f-822f-4a6a-8412-67e38be76bb8"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">Ventricular Fibrillation</span> in Patients With Accessory AV Pathway (Wolff-Parkinson-White Syndrome)</h2>
<p class="First">Patients with Wolff-Parkinson-White syndrome who develop <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> are at high risk of <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>. Treatment of these patients with digoxin leads to greater slowing of conduction in the atrioventricular node than in accessory pathways, and the risks of rapid ventricular response leading to <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> are thereby increased. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_866f103f-78b6-4c51-882b-7e94d5c74cf3"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus Bradycardia</span> and Sino-atrial Block</h2>
<p class="First">LANOXIN may cause severe <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span> or <span class="product-label-link" type="condition" conceptid="4277903" conceptname="Sinoatrial block">sinoatrial block</span> particularly in patients with pre-existing sinus node disease and may cause advanced or <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">complete heart block</span> in patients with pre-existing incomplete <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>. Consider insertion of a pacemaker before treatment with digoxin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f205b362-6aef-4293-b00d-ff36c4f56536"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Digoxin Toxicity</span></h2>
<p class="First">Signs and symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> include <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, visual changes and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> [first-degree, second-degree (<span class="product-label-link" type="condition" conceptid="318448" conceptname="Second degree atrioventricular block">Wenckebach</span>), or third-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> (including <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">asystole</span>); <span class="product-label-link" type="condition" conceptid="4171269" conceptname="Atrial tachycardia">atrial tachycardia</span> with block; <span class="product-label-link" type="condition" conceptid="4175473" conceptname="Atrioventricular dissociation">AV dissociation</span>; accelerated junctional (nodal) rhythm; unifocal or multiform ventricular premature contractions (especially <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">bigeminy</span> or <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">trigeminy</span>); <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>; and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>]. Toxicity is usually associated with digoxin levels greater than 2 ng/ml although symptoms may also occur at lower levels. Low body weight, advanced age or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> may predispose to <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span>. Obtain serum digoxin levels in patients with signs or symptoms of digoxin therapy and interrupt or adjust dose if necessary <span class="Italics">[see Adverse Reactions (<a href="#i4i_adverse_effects_id_28329907-90cb-40b1-bffd-89429ee3577f">6</a>) and Overdosage (<a href="#i4i_overdosage_id_48338721-8efd-4145-82c6-727724b7a632">10</a>)].</span> Assess serum electrolytes and renal function periodically. </p>
<p>The earliest and most frequent manifestation of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> in infants and children is the appearance of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, including <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>. In children, the use of digoxin may produce any <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>. The most common are conduction disturbances or supraventricular <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmias</span>, such as <span class="product-label-link" type="condition" conceptid="4171269" conceptname="Atrial tachycardia">atrial tachycardia</span> (with or without block) and junctional (nodal) <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular arrhythmias</span> are less common. <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus bradycardia</span> may be a sign of impending digoxin <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>, especially in infants, even in the absence of first-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>. Any <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> or alteration in cardiac conduction that develops in a child taking digoxin should initially be assumed to be a consequence of digoxin <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.</p>
<p>Given that adult patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> have some symptoms in common with <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span>, it may be difficult to distinguish <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> from <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Misidentification of their etiology might lead the clinician to continue or increase LANOXIN dosing, when dosing should actually be suspended. When the etiology of these signs and symptoms is not clear, measure serum digoxin levels.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_de7202af-caa6-4e9b-8874-2c13b4ca059e"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Risk of <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular Arrhythmias</span> During Electrical Cardioversion</h2>
<p class="First">It may be desirable to reduce the dose of or discontinue LANOXIN for 1 to 2Â days prior to electrical cardioversion of <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> to avoid the induction of <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, but physicians must consider the consequences of increasing the ventricular response if digoxin is decreased or withdrawn. If <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span> is suspected, elective cardioversion should be delayed. If it is not prudent to delay cardioversion, the lowest possible energy level should be selected to avoid provoking <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a442e88d-f067-416c-a0ef-ff37c4fc16e1"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Risk of <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">Ischemia</span> in Patients With <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span> </h2>
<p class="First">LANOXIN is not recommended in patients with <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> because digoxin may increase myocardial oxygen demand and lead to <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1f6f5128-3644-4e62-ae50-13c598344f51"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">Vasoconstriction</span> In Patients With <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span></h2>
<p class="First">LANOXIN can precipitate <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> and may promote production of pro-inflammatory cytokines; therefore, avoid use in patients with <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_73e766b3-5297-45b4-907d-c914508aa041"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Decreased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">Cardiac Output</span> in Patients With Preserved Left Ventricular Systolic Function</h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> associated with preserved left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> may experience decreased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> with use of LANOXIN. Such disorders include <span class="product-label-link" type="condition" conceptid="4190773" conceptname="Restrictive cardiomyopathy">restrictive cardiomyopathy</span>, <span class="product-label-link" type="condition" conceptid="312334" conceptname="Constrictive pericarditis">constrictive pericarditis</span>, amyloid heart disease, and <span class="product-label-link" type="condition" conceptid="312927" conceptname="Acute cor pulmonale">acute cor pulmonale</span>. Patients with <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">idiopathic hypertrophic subaortic stenosis</span> may have worsening of the outflow obstruction due to the inotropic effects of digoxin. Patients with amyloid heart disease may be more susceptible to <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> at therapeutic levels because of an increased binding of digoxin to extracellular amyloid fibrils. </p>
<p>LANOXIN should generally be avoided in these patients, although it has been used for ventricular rate control in the subgroup of patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9ba87268-9111-4f1e-8966-cb4d893c9970"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Reduced Efficacy In Patients With <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span> can nullify the effects of digoxin in humans; thus, digoxin may be ineffective until serum calcium is restored to normal. These interactions are related to the fact that digoxin affects contractility and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span> of the heart in a manner similar to that of calcium.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fd5c5d8f-f89b-47e7-b762-c4d075c60e94"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Altered Response in <span class="product-label-link" type="condition" conceptid="141253" conceptname="Disorder of thyroid gland">Thyroid Disorders</span> and Hypermetabolic States</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span> may reduce the requirements for digoxin. </p>
<p><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span> and/or <span class="product-label-link" type="condition" conceptid="4021776" conceptname="Atrial rhythm">atrial arrhythmias</span> resulting from hypermetabolic or hyperdynamic states (e.g., <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, or arteriovenous shunt) are best treated by addressing the underlying condition. <span class="product-label-link" type="condition" conceptid="4021776" conceptname="Atrial rhythm">Atrial arrhythmias</span> associated with hypermetabolic states are particularly resistant to digoxin treatment.  Patients with <span class="product-label-link" type="condition" conceptid="434620" conceptname="Beriberi">beri beri</span> heart disease may fail to respond adequately to digoxin if the underlying thiamine deficiency is not treated concomitantly.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_28329907-90cb-40b1-bffd-89429ee3577f"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are included in more detail in the Warnings and Precautions section of the label:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac arrhythmias</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_e63ec79f-822f-4a6a-8412-67e38be76bb8">5.1</a>, <a href="#i4i_section_id_866f103f-78b6-4c51-882b-7e94d5c74cf3">5.2</a>)]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Digoxin Toxicity</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_f205b362-6aef-4293-b00d-ff36c4f56536">5.3</a>)]</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_99f6a114-4476-4814-8122-937998ecd4c9"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>In general, the adverse reactions of LANOXIN are dose-dependent and occur at doses higher than those needed to achieve a therapeutic effect. Hence, adverse reactions are less common when LANOXIN is used within the recommended dose range, is maintained within the therapeutic serum concentration range, and when there is careful attention to concurrent medications and conditions.</p>
<p>In the DIG  trial (a trial investigating the effect of digoxin on mortality and morbidity in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>), the incidence of hospitalization for suspected <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> was 2% in patients taking LANOXIN compared to 0.9% in patients taking placebo <span class="Italics">[see Clinical Studies (<a href="#i4i_section_id_c3feced0-eba3-416d-b3a7-7f6458779ba3">14.1</a>)]</span>.  </p>
<p>The overall incidence of adverse reactions with digoxin has been reported as 5-20%, with 15-20% of adverse events considered serious. Cardiac toxicity accounts for about one-half, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> for about one-fourth, and CNS and other toxicity for about one-fourth of these adverse events. </p>
<p><span class="Italics">Gastrointestinal:</span> In addition to <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, the use of digoxin has been associated with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="192673" conceptname="Vascular insufficiency of intestine">intestinal ischemia</span>, and hemorrhagic <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> of the intestines.</p>
<p><span class="Italics">CNS:</span> Digoxin can cause <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, and mental disturbances (such as <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, and <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>).</p>
<p><span class="Italics">Other:</span> <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span> has been occasionally observed following the prolonged use of digoxin. <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span> and other <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> have been rarely observed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_b9013de6-caba-4ef4-8f0d-c2b818218d4b"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Digoxin has a narrow therapeutic index, increased monitoring of serum digoxin concentrations  and for potential signs and symptoms of clinical toxicity is necessary when initiating, adjusting, or discontinuing drugs that may interact with digoxin.  Prescribers should consult the prescribing information of any drug which is co-prescribed with digoxin for potential drug interaction information.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4394fdb7-2435-4f1d-b4e7-1ae9b1e4acfc"></a><a name="section-7.1"></a><p></p>
<h2>7.1 P-Glycoprotein (PGP) Inducers/Inhibitors</h2>
<p class="First">Digoxin is a substrate of P-glycoprotein. Drugs that induce or inhibit P-glycoprotein in intestine or kidney have the potential to alter digoxin pharmacokinetics. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3b3281f9-7c63-4d40-a2b3-fcf8b0bb1862"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Pharmacokinetic Drug Interactions</h2>
<table width="100%">
<col width="20%">
<col width="21%">
<col width="20%">
<col width="37%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">NA â€“ Not available/reported</td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Toprule" colspan="4" valign="top"><p class="First"><span class="Bold">Digoxin concentrations increased greater than 50%</span></p></td></tr>
<tr>
<td valign="top"></td>
<td align="center" valign="top"><p class="First">Â Â Â DigoxinÂ SerumÂ Â Â <br>Concentration Increase</p></td>
<td align="center" valign="top"><p class="First">Â Â Â DigoxinÂ AUCÂ Â Â <br>Increase</p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">Recommendations</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First">Amiodarone</p></td>
<td align="center" valign="top"><p class="First">70%</p></td>
<td align="center" valign="top"><p class="First">NA</p></td>
<td rowspan="8" valign="top"><p class="First">Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasingÂ doseÂ byÂ approximately 30-50% or by modifying the dosing frequency and continue monitoring. </p></td>
</tr>
<tr>
<td valign="top"><p class="First">Captopril </p></td>
<td align="center" valign="top"><p class="First">58%</p></td>
<td align="center" valign="top"><p class="First">39%</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Clarithromycin</p></td>
<td align="center" valign="top"><p class="First">NA</p></td>
<td align="center" valign="top"><p class="First">70%</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Dronedarone</p></td>
<td align="center" valign="top"><p class="First">NA</p></td>
<td align="center" valign="top"><p class="First">150%</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Gentamicin</p></td>
<td align="center" valign="top"><p class="First">129-212%</p></td>
<td align="center" valign="top"><p class="First">NA</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Erythromycin</p></td>
<td align="center" valign="top"><p class="First">100%</p></td>
<td align="center" valign="top"><p class="First">NA</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Itraconazole</p></td>
<td align="center" valign="top"><p class="First">80%</p></td>
<td align="center" valign="top"><p class="First">NA</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Nitrendipine</p></td>
<td align="center" valign="top"><p class="First">57%</p></td>
<td align="center" valign="top"><p class="First">15%</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Propafenone</p></td>
<td align="center" valign="top"><p class="First">NA</p></td>
<td align="center" valign="top"><p class="First">60-270%</p></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top"><p class="First">Quinidine</p></td>
<td align="center" valign="top"><p class="First">100%</p></td>
<td align="center" valign="top"><p class="First">NA</p></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top"><p class="First">Ranolazine</p></td>
<td align="center" valign="top"><p class="First">50%</p></td>
<td align="center" valign="top"><p class="First">NA</p></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top"><p class="First">Ritonavir</p></td>
<td align="center" valign="top"><p class="First">NA</p></td>
<td align="center" valign="top"><p class="First">86%</p></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top"><p class="First">Tetracycline</p></td>
<td align="center" valign="top"><p class="First">100%</p></td>
<td align="center" valign="top"><p class="First">NA</p></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top"><p class="First">Verapamil</p></td>
<td align="center" valign="top"><p class="First">50-75%</p></td>
<td align="center" valign="top"><p class="First">NA</p></td>
<td valign="top"></td>
</tr>
<tr><td colspan="4" valign="top"><p class="First"><span class="Bold">Digoxin concentrations increased less than 50%</span></p></td></tr>
<tr>
<td valign="top"><p class="First">Atorvastatin</p></td>
<td align="center" valign="top"><p class="First">22%</p></td>
<td align="center" valign="top"><p class="First">15%</p></td>
<td rowspan="8" valign="top"><p class="First">Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing the dose by approximately 15-30% or by modifying the dosing frequency and continue monitoring.</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Carvedilol</p></td>
<td align="center" valign="top"><p class="First">16%</p></td>
<td align="center" valign="top"><p class="First">14%</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Diltiazem</p></td>
<td align="center" valign="top"><p class="First">20%</p></td>
<td align="center" valign="top"><p class="First">NA</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Indomethacin</p></td>
<td align="center" valign="top"><p class="First">40%</p></td>
<td align="center" valign="top"><p class="First">NA</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Nefazodone</p></td>
<td align="center" valign="top"><p class="First">27%</p></td>
<td align="center" valign="top"><p class="First">15%</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Nifedipine</p></td>
<td align="center" valign="top"><p class="First">45%</p></td>
<td align="center" valign="top"><p class="First">NA</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Propantheline</p></td>
<td align="center" valign="top"><p class="First">24%</p></td>
<td align="center" valign="top"><p class="First">24%</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Quinine</p></td>
<td align="center" valign="top"><p class="First">NA</p></td>
<td align="center" valign="top"><p class="First">33%</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Saquinavir</p></td>
<td align="center" valign="top"><p class="First">27%</p></td>
<td align="center" valign="top"><p class="First">49%</p></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top"><p class="First">SpironolactoneÂ Â Â Â Â </p></td>
<td align="center" valign="top"><p class="First">25%</p></td>
<td align="center" valign="top"><p class="First">NA</p></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top"><p class="First">Telmisartan</p></td>
<td align="center" valign="top"><p class="First">20-49%</p></td>
<td align="center" valign="top"><p class="First">NA</p></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top"><p class="First">Tolvaptan</p></td>
<td align="center" valign="top"><p class="First">30%</p></td>
<td align="center" valign="top"><p class="First">NA</p></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top"><p class="First">Trimethoprim</p></td>
<td align="center" valign="top"><p class="First">22-28%</p></td>
<td align="center" valign="top"><p class="First">NA</p></td>
<td valign="top"></td>
</tr>
<tr><td colspan="4" valign="top"><p class="First"><span class="Bold">Digoxin concentrations increased, but magnitude is unclear</span></p></td></tr>
<tr>
<td colspan="3" valign="top"><p class="First">Alprazolam, azithromycin, cyclosporine, diclofenac, <br>diphenoxylate, epoprostenol, esomeprazole, ibuprofen, <br>ketoconazole, lansoprazole, metformin, omeprazole, <br>rabeprazole, </p></td>
<td valign="top"><p class="First">Measure serum digoxin concentrations before initiating concomitant drugs. Continue monitoring and reduce digoxin dose as necessary.</p></td>
</tr>
<tr><td colspan="4" valign="top"><p class="First"><span class="Bold">Digoxin concentrations decreased</span></p></td></tr>
<tr>
<td colspan="3" valign="top"><p class="First">Acarbose, activated charcoal, albuterol, antacids, certain <br>cancer chemotherapy or radiation therapy, cholestyramine, <br>colestipol, extenatide, kaolin-pectin, meals high in bran, <br>metoclopramide, miglitol, neomycin, penicillamine, <br>phenytoin, rifampin, St.Â Johnâ€™s Wort, sucralfate, <br>sulfasalazine</p></td>
<td valign="top"><p class="First">Measure serum digoxin concentrations before initiating concomitant drugs. Continue monitoring and increase digoxin dose by approximately 20-40% as necessary.</p></td>
</tr>
<tr><td colspan="4" valign="top"><p class="First"><span class="Bold">No significant Digoxin exposure changes</span></p></td></tr>
<tr class="Last">
<td class="Botrule" colspan="3" valign="top"><p class="First">PleaseÂ referÂ toÂ sectionÂ 12Â forÂ aÂ completeÂ listÂ ofÂ drugsÂ whichÂ Â Â Â Â <br>were studied but reported no significant changes on digoxin exposure.</p></td>
<td class="Botrule" valign="top"><p class="First">NoÂ additionalÂ actionsÂ areÂ required.Â Â Â Â Â </p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_281cc437-7c81-478b-b7f7-91bcbae4ff98"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Potentially Significant Pharmacodynamic Drug Interactions</h2>
<p class="First">Because of considerable variability of <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interactions</span>, the dosage of digoxin should be individualized when patients receive these medications concurrently.</p>
<table width="100%">
<col width="36%">
<col width="20%">
<col width="41%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" valign="top"><p class="First">Drugs that Affect Renal Function</p></td>
<td class="Botrule Toprule" colspan="2" valign="top"><p class="First">A decline in GFR or tubular secretion, as from ACE inhibitors, angiotensin receptor blockers, nonsteroidal anti-inflammatory drugs [NSAIDS], COX-2 inhibitors may impair the excretion of digoxin.</p></td>
</tr>
<tr>
<td class="Botrule" valign="top"><p class="First">Antiarrthymics</p></td>
<td class="Botrule" valign="top"><p class="First">Dofetilide</p></td>
<td class="Botrule" valign="top"><p class="First">Concomitant administration with digoxin was associated with a higher rate of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span></p></td>
</tr>
<tr>
<td class="Botrule" valign="top"></td>
<td class="Botrule" valign="top"><p class="First">Sotalol</p></td>
<td class="Botrule" valign="top"><p class="First">Proarrhythmic events were more common in patients receiving sotalol and digoxin than on either alone; it is not clear whether this represents an interaction or is related to the presence of CHF, a known risk factor for <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">proarrhythmia</span>, in patients receiving digoxin.</p></td>
</tr>
<tr>
<td class="Botrule" valign="top"></td>
<td class="Botrule" valign="top"><p class="First">Dronedarone</p></td>
<td class="Botrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">Sudden death</span> was more common in patients receiving digoxin with dronedarone than on either alone; it is not clear whether this represents an interaction or is related to the presence of advanced heart disease, a known risk factor for <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> in patients receiving digoxin. </p></td>
</tr>
<tr>
<td class="Botrule" valign="top"><p class="First">Parathyroid Hormone Analog</p></td>
<td class="Botrule" valign="top"><p class="First">Teriparatide</p></td>
<td class="Botrule" valign="top"><p class="First">Sporadic case reports have suggested that <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> may predispose patients to <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span>. Teriparatide transiently increases serum calcium.</p></td>
</tr>
<tr>
<td class="Botrule" valign="top"><p class="First">Thyroid supplement</p></td>
<td class="Botrule" valign="top"><p class="First">Thyroid</p></td>
<td class="Botrule" valign="top"><p class="First">Treatment of <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> in patients taking digoxin may increase the dose requirements of digoxin.</p></td>
</tr>
<tr>
<td class="Botrule" valign="top"><p class="First">Sympathomimetics</p></td>
<td class="Botrule" valign="top"><p class="First">Epinephrine<br>NorepinephrineÂ Â Â Â Â <br>Dopamine</p></td>
<td class="Botrule" valign="top"><p class="First">Can increase the risk of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span></p></td>
</tr>
<tr>
<td class="Botrule" valign="top"><p class="First">NeuromuscularÂ BlockingÂ AgentsÂ Â Â Â Â </p></td>
<td class="Botrule" valign="top"><p class="First">Succinylcholine</p></td>
<td class="Botrule" valign="top"><p class="First">May cause sudden extrusion of potassium from muscle cells causing <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> in patients taking digoxin.</p></td>
</tr>
<tr>
<td class="Botrule" valign="top"><p class="First">Supplements</p></td>
<td class="Botrule" valign="top"><p class="First">Calcium</p></td>
<td class="Botrule" valign="top"><p class="First">If administered rapidly by intravenous route, can produce serious <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> in digitalized patients.</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">Beta-adrenergic blockers and calcium channel blockers</p></td>
<td class="Botrule" valign="top"></td>
<td class="Botrule" valign="top"><p class="First">Additive effects on AV node conduction can result in <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and advanced or <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">complete heart block</span>.</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6fed24c4-0844-4365-81e6-3ea33fce8e0e"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Drug/Laboratory Test Interactions</h2>
<p class="First">Endogenous substances of unknown composition (digoxin-like immunoreactive substances, [DLIS]) can interfere with standard radioimmunoassays for digoxin. The interference most often causes results to be falsely positive or falsely elevated, but sometimes it causes results to be falsely reduced. Some assays are more subject to these failings than others. Several LC/MS/MS methods are available that may provide less susceptibility to DLIS interference. DLIS are present in up to half of all neonates and in varying percentages of pregnant women, patients with <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">hypertrophic cardiomyopathy</span>, patients with renal or hepatic dysfunction, and other patients who are volume-expanded for any reason. The measured levels of DLIS (as digoxin equivalents) are usually low (0.2-0.4 ng/mL), but sometimes they reach levels that would be considered therapeutic or even toxic. </p>
<p>In some assays, spironolactone, canrenone, and potassium canrenoate may be falsely detected as digoxin, at levels up to 0.5 ng/mL. Some traditional Chinese and Ayurvedic medicine substances like Chan Su, Siberian Ginseng, Asian Ginseng, Ashwagandha or Dashen, can cause similar interference. </p>
<p>Spironolactone and DLIS are much more extensively protein-bound than digoxin. As a result, assays of free digoxin levels in protein-free ultrafiltrate (which tend to be about 25% less than total levels, consistent with the usual extent of protein binding) are less affected by spironolactone or DLIS. It should be noted that ultrafiltration does not solve all interference problems with alternative medicines. The use of an LC/MS/MS method may be the better option according to the good results it provides, especially in terms of specificity and limit of quantization.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_8f27307b-aff1-4d61-8c0b-60b9c6a3dfae"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_5ce90afc-2f1e-45e1-be10-c935e8f18824"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9ff3dc66-c6e6-4ee2-aee9-786c588d06e7"></a><a name="section-8.1.1"></a><p></p>
<h3><span class="Bold">Pregnancy Category C.</span></h3>
<p class="First">LANOXIN should be given to a pregnant woman only if clearly needed.  It is also not known whether digoxin can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Animal reproduction studies have not been conducted with digoxin.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_511893fb-4521-4669-bc12-2ecbeccd8945"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">There are not enough data from clinical trials to determine the safety and efficacy of digoxin during labor and delivery.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_9819a383-32cd-405f-992f-1478f2a0806b"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Studies have shown that digoxin distributes into breast milk, and that the milk-to-serum concentration ratio is approximately 0.6-0.9. However, the estimated exposure of a nursing infant to digoxin via breastfeeding is far below the usual infant maintenance dose. Therefore, this amount should have no pharmacologic effect upon the infant. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_e712826b-1db0-4c21-8a8b-408a55cc6e26"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of LANOXIN in the control of ventricular rate in children with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> have not been established.</p>
<p>The safety and effectiveness of LANOXIN in the treatment of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> in children have not been established in adequate and well-controlled studies. However, in published literature of children with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> of various etiologies (e.g., <span class="product-label-link" type="condition" conceptid="434462" conceptname="Ventricular septal defect">ventricular septal defects</span>, anthracycline toxicity, <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span>), treatment with digoxin has been associated with improvements in hemodynamic parameters and in clinical signs and symptoms.</p>
<p>Newborn infants display considerable variability in their tolerance to digoxin. Premature and immature infants are particularly sensitive to the effects of digoxin, and the dosage of the drug must not only be reduced but must be individualized according to their degree of maturity.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_f80a0adf-1994-4c4f-b6c2-8c6c9a14576b"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">The majority of clinical experience gained with digoxin has been in the elderly population. This experience has not identified differences in response or adverse effects between the elderly and younger patients. However, this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, which should be based on renal function, and it may be useful to monitor renal function <span class="Italics">[see Dosage and Administration (<a href="#i4i_section_id_75d31293-0976-48df-8999-c40e338fcbc9">2.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_eb9bb812-458c-49d5-a474-cbda03b4a949"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The clearance of digoxin can be primarily correlated with the renal function as indicated by creatinine clearance. Tables 3 and 5 provide the usual daily maintenance dose requirements for digoxin based on creatinine clearance <span class="Italics">[see Dosage and Administration (<a href="#i4i_section_id_ddbda300-49f7-4e82-88c3-80fc831e8771">2.3</a>)]</span>.</p>
<p>Digoxin is primarily excreted by the kidneys; therefore, patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> require smaller than usual maintenance doses of digoxin <span class="Italics">[see Dosage and Administration (<a href="#i4i_section_id_ddbda300-49f7-4e82-88c3-80fc831e8771">2.3</a>)]</span>. Because of the prolonged elimination half-life, a longer period of time is required to achieve an initial or new steady-state serum concentration in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> than in patients with normal renal function. If appropriate care is not taken to reduce the dose of digoxin, such patients are at high risk for toxicity, and toxic effects will last longer in such patients than in patients with normal renal function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_75bf52ad-b4fb-49d7-8f5b-357478eceff0"></a><a name="section-8.7"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Plasma digoxin concentrations in patients with acute <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> generally <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> within the range of profiles in a group of healthy subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8db4a16f-b6bd-4a6f-9bef-98160cfe87c5"></a><a name="section-8.8"></a><p></p>
<h2>8.8 <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">Malabsorption</span></h2>
<p class="First">The absorption of digoxin is reduced in some <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span> conditions such as <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">chronic diarrhea</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_48338721-8efd-4145-82c6-727724b7a632"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f96b376f-0df3-4179-bf5a-016134eae11c"></a><a name="section-9.1"></a><p></p>
<h2>10.1 Signs and Symptoms in Adults and Children</h2>
<p class="First">The signs and symptoms of toxicity are generally similar to those described in the Adverse Reactions (<a href="#i4i_section_id_99f6a114-4476-4814-8122-937998ecd4c9">6.1</a>) but may be more frequent and can be more severe. Signs and symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> become more frequent with levels above 2Â ng/mL. However, in deciding whether a patientâ€™s symptoms are due to digoxin, the clinical state together with serum electrolyte levels and thyroid function are important factors <span class="Italics">[see Dosage and Administration (<a href="#i4i_dosage_admin_id_fdb0cad7-dcff-452a-8d2f-feaafee383c1">2</a>)]</span>. </p>
<p><span class="Underline">Adults:</span> The most common signs and symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> that occur in 30-70% of patients who are overdosed. Extremely high serum concentrations produce <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> especially in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Almost every type of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span> has been associated with digoxin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and multiple rhythm disturbances in the same patient are common. Peak cardiac effects occur 3-6 hours following ingestion and may persist for 24Â hours or longer. <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span> that are considered more characteristic of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> are new-onset Mobitz type 1 A-V block, accelerated <span class="product-label-link" type="condition" conceptid="4038688" conceptname="AV junctional rhythm">junctional rhythms</span>, non-paroxysmal <span class="product-label-link" type="condition" conceptid="4171269" conceptname="Atrial tachycardia">atrial tachycardia</span> with A-V block, and bi-directional <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>. <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span> from <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">asystole</span> or <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> is usually fatal. </p>
<p><span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Digoxin toxicity</span> is related to serum concentration. As digoxin serum levels increase above 1.2Â ng/mL, there is a potential for increase in adverse reactions. Furthermore, lower potassium levels increases the risk for adverse reactions. In adults with heart disease, clinical observations suggest that an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of digoxin of 10-15 mg results in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of half of patients. A dose above 25Â mg ingested by an adult without heart disease appeared to be uniformly fatal if no Digoxin Immune Fab (DIGIBINDÂ®, DIGIFABÂ®) was administered. </p>
<p>Among the extra-cardiac manifestations, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>) are very common (up to 80% incidence) and precede cardiac manifestations in approximately half of the patients in most literature reports. Neurologic manifestations (e.g.,Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, various CNS disturbances), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> are very common. Visual manifestations may also occur with aberration in color vision (predominance of yellow green) the most frequent. Neurological and visual symptoms may persist after other signs of toxicity have resolved. In chronic toxicity, non-specific extra-cardiac symptoms, such as <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, may predominate.</p>
<p><span class="Underline">Children:</span> In pediatric patients, signs and symptoms of toxicity can occur during or shortly after the dose of digoxin. Frequent non-cardiac effects are similar to those observed in adults although <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> are not seen frequently in infants and small pediatric patients. Other reported manifestations of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> in older age groups, <span class="product-label-link" type="condition" conceptid="437986" conceptname="Failure to thrive">failure to thrive</span> in infants, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> caused by mesenteric artery <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, and behavioral disturbances including <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic episodes</span>. <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span> and combinations of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> that occur in adult patients can also occur in pediatric patients although <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>, and rapid <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> are seen less frequently in pediatric patients. Pediatric patients are more likely to develop A-V conduction disturbances, or <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>. Any <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> in a child treated with digoxin should be considered related to digoxin until otherwise ruled out. In pediatric patients aged 1-3 years without heart disease, clinical observations suggest that an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of digoxin of 6-10 mg would result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of half of the patients. In the same population, a dose above 10 mg resulted in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> if no Digoxin Immune Fab were administered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a3f66d12-94df-40e5-87dd-05569b51c9db"></a><a name="section-9.2"></a><p></p>
<h2>10.2 Treatment</h2>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Chronic Overdose</span> </span></p>
<p>If there is suspicion of toxicity, discontinue LANOXIN and place the patient on a cardiac monitor. Correct factors such as electrolyte abnormalities, thyroid dysfunction, and concomitant medications <span class="Italics">[see Dosage and Administration (<a href="#i4i_section_id_bf18b8a3-beb9-4adf-82bd-17727e091d65">2.5</a>)]. </span>Correct <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> by administering potassium so that serum potassium is maintained between 4.0 and 5.5 mmol/L. Potassium is usually administered orally, but when correction of the <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> is urgent and serum potassium concentration is low, potassium may be administered by the intravenous route. Monitor electrocardiogram for any evidence of potassium toxicity (e.g., peaking of T waves) and to observe the effect on the <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>. Avoid potassium salts in patients with <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> or <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>. Symptomatic <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> may be treated with Digoxin Immune Fab.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Acute Overdose</span> </span></p>
<p>Patients who have intentionally or accidently ingested massive doses of digoxin should receive activated charcoal orally or by nasogastric tube regardless of the time since ingestion since digoxin recirculates to the intestine by enterohepatic circulation. In addition to cardiac monitoring, temporarily discontinue LANOXIN until the adverse reaction resolves. Correct factors that may be contributing to the adverse reactions <span class="Italics">[see Warnings and Precautions (<a href="#i4i_warnings_precautions_id_d3853e2c-c99a-4eef-b8a5-6d3308004dc0">5</a>)]</span>. In particular, correct <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>. Digoxin is not effectively removed from the body by dialysis because of its large extravascular volume of distribution. Life threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> (<span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, high degree A-V block, bradyarrhythma, <span class="product-label-link" type="condition" conceptid="4210313" conceptname="Sinus arrest">sinus arrest</span>) or <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> requires administration of Digoxin Immune Fab. Digoxin Immune Fab has been shown to be 80-90% effective in reversing signs and symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span>. <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> caused by digoxin are parasympathetically mediated and respond to atropine. A temporary cardiac pacemaker may also be used. <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular arrhythmias</span> may respond to lidocaine or phenytoin. When a large amount of digoxin has been ingested, especially in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> may be present due to release of potassium from skeletal muscle. In this case, treatment with Digoxin Immune Fab is indicated; an initial treatment with glucose and insulin may be needed if the <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> is life-threatening. Once the adverse reaction has resolved, therapy with LANOXIN may be reinstituted following a careful reassessment of dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_0b1429f1-c6ab-4bef-95d7-88ab98369983"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">LANOXIN (digoxin) is one of the cardiac (or digitalis) glycosides, a closely related group of drugs having in common specific effects on the myocardium.Â  These drugs are found in a number of plants. Digoxin is extracted from the leaves of <span class="Italics">Digitalis lanata</span>. The term â€œdigitalisâ€? is used to designate the whole group of glycosides. The glycosides are composed of 2 portions: a sugar and a cardenolide (hence â€œglycosidesâ€?).</p>
<p>Digoxin is described chemically as (3Î²,5Î²,12Î²)-3-[(<span class="Italics">O</span>-2,6-dideoxy-Î²-<span class="Italics">D-ribo</span>-hexopyranosyl-(1â†’4)-<span class="Italics">O</span>-2,6-dideoxy-Î²-<span class="Italics">D-ribo-</span>hexopyranosyl-(1â†’4)-2,6-dideoxy-Î²-<span class="Italics">D</span>-<span class="Italics">ribo</span>-hexopyranosyl)oxy]-12,14-dihydroxy-card-20(22)-enolide. Its molecular formula is C<span class="Sub">41</span>H<span class="Sub">64</span>O<span class="Sub">14</span>, its molecular weight is 780.95, and its structural formula is:</p>
<div class="Figure">
<a name="id1418"></a><img alt="Structural Formula " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0b96049b-e6b9-4ebb-bfe9-d5a73ed4f66b&amp;name=image-01.jpg">
</div>
<p>Digoxin exists as odorless white crystals that melt with decomposition above 230Â°C. The drug is practically insoluble in water and in ether; slightly soluble in diluted (50%) alcohol and in chloroform; and freely soluble in pyridine.</p>
<p>LANOXIN is supplied as 62.5 mcg (unscored), 125 mcg (scored), 187.5 mcg (unscored), and 250 mcg (scored) tablets for oral administration.  Each tablet contains the labeled amount of digoxin USP and the following inactive ingredients: corn and potato starches, lactose and magnesium stearate.  The 125 mcg tablets contain D&amp;C Yellow No. 10 and FD&amp;C Yellow No.Â 6, the 62.5 mcg tablets contain FD&amp;C Yellow No. 6 and the 187.5 mcg tablets contain D&amp;C Green Dye No. 5.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_9e6a0a2b-5767-480c-a802-1456191687d2"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_5ea2560d-67f0-416b-9d32-3cda3fa86d28"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">All of digoxinâ€™s actions are mediated through its effects on Na-K ATPase. This enzyme, the â€œsodium pump,â€? is responsible for maintaining the intracellular milieu throughout the body by moving sodium ions out of and potassium ions into cells. By inhibiting Na-K ATPase, digoxin </p>
<dl>
<dt>â€¢</dt>
<dd>causes increased availability of intracellular calcium in the myocardium and conduction system, with consequent increased inotropy, increased automaticity, and reduced conduction velocity</dd>
<dt>â€¢</dt>
<dd>indirectly causes parasympathetic stimulation of the autonomic nervous system, with consequent effects on the sino-atrial (SA) and atrioventricular (AV) nodes</dd>
<dt>â€¢</dt>
<dd>reduces catecholamine reuptake at nerve terminals, rendering blood vessels more sensitive to endogenous or exogenous catecholamines</dd>
<dt>â€¢</dt>
<dd>increases baroreceptor sensitization, with consequent increased carotid sinus nerve activity and enhanced sympathetic withdrawal for any given increment in mean arterial pressure</dd>
<dt>â€¢</dt>
<dd>increases (at higher concentrations) sympathetic outflow from the central nervous system (CNS) to both cardiac and peripheral sympathetic nerves</dd>
<dt>â€¢</dt>
<dd>allows (at higher concentrations) progressive efflux of intracellular potassium, with consequent increase in serum potassium levels. </dd>
</dl>
<p>The cardiologic consequences of these direct and indirect effects are an increase in the force and velocity of myocardial systolic contraction (positive inotropic action), a slowing of the heart rate (negative chronotropic effect), decreased conduction velocity through the AV node, and a decrease in the degree of activation of the sympathetic nervous system and renin-angiotensin system (neurohormonal deactivating effect). </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_c2e1a2f6-6317-4887-98e0-fd613bb79e7c"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">The times to onset of pharmacologic effect and to peak effect of preparations of LANOXIN are shown in <a href="#_Ref370220625">Table 7</a>.</p>
<a name="_Ref370220625"></a><table width="100%">
<caption><span>Table 7. Times to Onset of Pharmacologic Effect and to Peak Effect of Preparations of LANOXIN</span></caption>
<col width="38%">
<col width="31%">
<col width="31%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="3" valign="top">
<span class="Sup">a</span>Â Â Documented for ventricular response rate in <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, inotropic effects and electrocardiographic changes.<br><span class="Sup">b</span>Â Â Depending upon rate of infusion.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First"><span class="Bold">Product</span></p></td>
<td class="Toprule" align="center" valign="top"><p class="First"><span class="Bold">TimeÂ toÂ OnsetÂ ofÂ Effect<span class="Sup">a</span></span></p></td>
<td class="Toprule" align="center" valign="top"><p class="First"><span class="Bold">TimeÂ toÂ PeakÂ Effect<span class="Sup">a</span></span></p></td>
</tr>
<tr>
<td valign="top"><p class="First">LANOXIN Tablets</p></td>
<td align="center" valign="top"><p class="First">0.5-2 hours</p></td>
<td align="center" valign="top"><p class="First">2-6 hours</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">LANOXINÂ Injection/IVÂ Â Â Â Â </p></td>
<td class="Botrule" align="center" valign="top"><p class="First">5-30 minutes<span class="Sup">b</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">1-4 hours</p></td>
</tr>
</tbody>
</table>
<p><span class="Underline">Hemodynamic Effects:</span> Short- and long-term therapy with the drug increases <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and lowers pulmonary artery pressure, pulmonary capillary wedge pressure, and systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. These hemodynamic effects are accompanied by an increase in the left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> and a decrease in end-systolic and end-diastolic dimensions.</p>
<p><span class="Underline">ECG Changes:</span> The use of therapeutic doses of LANOXIN may cause prolongation of the PR interval and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the ST segment on the electrocardiogram. LANOXIN may produce false positive ST-T changes on the electrocardiogram during exercise testing. These electrophysiologic effects are not indicative of toxicity. LANOXIN does not significantly reduce heart rate during exercise.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_3e1e0190-dd10-42a4-a02b-1d0e6d8dac15"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Note: The following data are from studies performed in adults, unless otherwise stated.</p>
<p><span class="Underline">Absorption:</span> Following oral administration, peak serum concentrations of digoxin occur at 1 to 3Â hours. Absorption of digoxin from LANOXIN Tablets has been demonstrated to be 60-80% complete compared to an identical intravenous dose of digoxin (absolute bioavailability). When LANOXIN Tablets are taken after meals, the rate of absorption is slowed, but the total amount of digoxin absorbed is usually unchanged. When taken with meals high in bran fiber, however, the amount absorbed from an oral dose may be reduced. Comparisons of the systemic availability and equivalent doses for oral preparations of LANOXIN are shown in Dosage and Administration (<a href="#i4i_section_id_142a1a90-3f30-4872-94f1-598bd749a504">2.6</a>).</p>
<p>Digoxin is a substrate for P-glycoprotein. As an efflux protein on the apical membrane of enterocytes, P-glycoprotein may limit the absorption of digoxin.</p>
<p>In some patients, orally administered digoxin is converted to inactive reduction products (e.g., dihydrodigoxin) by colonic bacteria in the gut. Data suggest that 1 in 10Â patients treated with digoxin tablets, colonic bacteria will degrade 40% or more of the ingested dose. As a result, certain antibiotics may increase the absorption of digoxin in such patients. Although inactivation of these bacteria by antibiotics is rapid, the serum digoxin concentration will rise at a rate consistent with the elimination half-life of digoxin. Serum digoxin concentration relates to the extent of bacterial inactivation, and may be as much as doubled in some cases <span class="Italics">[see Drug Interactions (<a href="#ID_3b3281f9-7c63-4d40-a2b3-fcf8b0bb1862">7.2</a>)]</span>.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption syndromes</span> (e.g., short bowel syndrome, celiac <span class="product-label-link" type="condition" conceptid="194992" conceptname="Celiac disease">sprue</span>, jejunoileal bypass) may have a reduced ability to absorb orally administered digoxin.</p>
<p><span class="Underline">Distribution:</span> Following drug administration, a 6-8 hour tissue distribution phase is observed. This is followed by a much more gradual decline in the serum concentration of the drug, which is dependent on the elimination of digoxin from the body. The peak height and slope of the early portion (absorption/distribution phases) of the serum concentration-time curve are dependent upon the route of administration and the absorption characteristics of the formulation. Clinical evidence indicates that the early high serum concentrations do not reflect the concentration of digoxin at its site of action, but that with chronic use, the steady-state post-distribution serum concentrations are in equilibrium with tissue concentrations and correlate with pharmacologic effects. In individual patients, these post-distribution serum concentrations may be useful in evaluating therapeutic and toxic effects <span class="Italics">[see Dosage and Administration (<a href="#i4i_section_id_75d31293-0976-48df-8999-c40e338fcbc9">2.1</a>)]</span>.</p>
<p>Digoxin is concentrated in tissues and therefore has a large apparent volume of distribution (approximately 475-500 L). Digoxin crosses both the blood-brain barrier and the placenta. At delivery, the serum digoxin concentration in the newborn is similar to the serum concentration in the mother. Approximately 25% of digoxin in the plasma is bound to protein. Serum digoxin concentrations are not significantly altered by large changes in fat tissue weight, so that its distribution space correlates best with lean (i.e., ideal) body weight, not total body weight.</p>
<p><span class="Underline">Metabolism:</span> Only a small percentage (13%) of a dose of digoxin is metabolized in healthy volunteers. The urinary metabolites, which include dihydrodigoxin, digoxigenin bisdigitoxoside, and their glucuronide and sulfate conjugates, are polar in nature and are postulated to be formed via hydrolysis, oxidation, and conjugation. The metabolism of digoxin is not dependent upon the cytochrome P-450 system, and digoxin is not known to induce or inhibit the cytochrome P-450 system.</p>
<p><span class="Underline">Excretion:</span> Elimination of digoxin follows first-order kinetics (that is, the quantity of digoxin eliminated at any time is proportional to the total body content). Following intravenous administration to healthy volunteers, 50-70% of a digoxin dose is excreted unchanged in the urine. Renal excretion of digoxin is proportional to creatinine clearance and is largely independent of urine flow. In healthy volunteers with normal renal function, digoxin has a half-life of 1.5-2Â days. The half-life in anuric patients is prolonged to 3.5-5Â days. Digoxin is not effectively removed from the body by dialysis, exchange transfusion, or during cardiopulmonary bypass because most of the drug is bound to extravascular tissues.</p>
<p><span class="Underline">Special Populations:</span><span class="Italics">Geriatrics:</span> Because of age-related declines in renal function, elderly patients would be expected to eliminate digoxin more slowly than younger subjects. Elderly patients may also exhibit a lower volume of distribution of digoxin due to age-related loss of lean <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle mass</span>. Thus, the dosage of digoxin should be carefully selected and monitored in elderly patients <span class="Italics">[see Use in Specific Populations (<a href="#i4i_geriatric_use_id_f80a0adf-1994-4c4f-b6c2-8c6c9a14576b">8.5</a>)]</span>. </p>
<p><span class="Italics">Gender:</span> In a study of 184 patients, the clearance of digoxin was 12% lower in female than in male patients. This difference is not likely to be clinically important. </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> Because only a small percentage (approximately 13%) of a dose of digoxin undergoes metabolism, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> would not be expected to significantly alter the pharmacokinetics of digoxin. In a small study, plasma digoxin concentration profiles in patients with acute <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> generally fell within the range of profiles in a group of healthy subjects. No dosage adjustments are recommended for patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>; however, serum digoxin concentrations should be used as appropriate to help guide dosing in these patients.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> Since the clearance of digoxin correlates with creatinine clearance, patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> generally demonstrate prolonged digoxin elimination half-lives and greater exposures to digoxin. Therefore, titrate carefully in these patients based on clinical response, and based on monitoring of serum digoxin concentrations, as appropriate.</p>
<p><span class="Italics">Race:</span> The impact of race differences on digoxin pharmacokinetics have not been formally studied. Because digoxin is primarily eliminated as unchanged drug via the kidney and because there are no important differences in creatinine clearance among races, pharmacokinetic differences due to race are not expected.</p>
<p><span class="Italics"><span class="Underline">Drug-drug Interactions</span></span></p>
<p>Based on literature reports no significant changes in digoxin exposure were reported when digoxin was co-administered with the following drugs:</p>
<p>alfuzosin, aliskiren, amlodipine, aprepitant, argatroban, aspirin, atorvastatin, benazepril, bisoprolol, black cohosh, bosentan, candesartan, citalopram, clopidogrel, colesevelam, dipyridamole, disopyramide, donepezil, doxazosin, dutasteride, echinacea, enalapril, eprosartan, ertapenem, escitalopram, esmolol, ezetimibe, famciclovir, felodipine, finasteride, flecainide, fluvastatin, fondaparinux, galantamine, gemifloxacin, grapefruit juice, irbesartan, isradipine, ketorlac, levetiracetam, levofloxacin, lisinopril, losartan, lovastatin, meloxicam, mexilitine, midazolam, milk thistle, moexipril, montelukast, moxifloxacin, mycophenolate, nateglinide, nesiritide, nicardipine, nisoldipine, olmesartan, orlistat, pantoprazole, paroxetine, perindopril, pioglitazone, pravastatin, prazosin, procainamide, quinapril, raloxifene, ramipril, repaglinide, rivastigmine, rofecoxib, ropinirole, rosiglitazone, rosuvastatin, sertraline, sevelamer, simvastatin, sirolimus, solifenacin, tamsulosin, tegaserod, terbinafine, tiagabine, ticlopidine, tigecycline, topiramate, torsemide, tramadol, trandolapril, triamterene, trospium, trovafloxacin, valacyclovir, valsartan, varenicline, voriconazole, zaleplon, zolpidem</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_11936699-8500-4b80-8056-2f5f7810a4ac"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_5bb20663-00b9-4aa8-8643-9c90be70eb13"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Digoxin showed no genotoxic potential in <span class="Italics">in vitro</span> studies (Ames test and mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>). No data are available on the carcinogenic potential of digoxin, nor have studies been conducted to assess its potential to affect fertility.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_28bbcac1-cdd0-4fa3-8037-87b1d892d38a"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c3feced0-eba3-416d-b3a7-7f6458779ba3"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Chronic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></h2>
<p class="First">Two 12-week, double-blind, placebo-controlled studies enrolled 178 (RADIANCE trial) and 88 (PROVED trial) adult patients with NYHA Class II or III <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> previously treated with oral digoxin, a diuretic, and an ACE inhibitor (RADIANCE only) and randomized them to placebo or treatment with LANOXIN Tablets. Both trials demonstrated better preservation of exercise capacity in patients randomized to LANOXIN. Continued treatment with LANOXIN reduced the risk of developing worsening <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, as evidenced by <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>-related hospitalizations and emergency care and the need for concomitant <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> therapy. </p>
<p><span class="Italics"><span class="Underline">DIG Trial of LANOXIN in Patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></span></span></p>
<p>The Digitalis Investigation Group (DIG) main trial was a 37-week, multicenter, randomized, double-blind mortality study comparing digoxin to placebo in 6800 adult patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> less than or equal to 0.45. At randomization, 67% were NYHA class I or II, 71% had <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> of ischemic etiology, 44% had been receiving digoxin, and most were receiving a concomitant ACE inhibitor (94%) and diuretics (82%). As in the smaller trials described above, patients who had been receiving open-label digoxin were withdrawn from this treatment before randomization. Randomization to digoxin was again associated with a significant reduction in the incidence of hospitalization, whether scored as number of hospitalizations for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (relative risk 75%), risk of having at least one such hospitalization during the trial (RR 72%), or number of hospitalizations for any cause (RR 94%). On the other hand, randomization to digoxin had no apparent effect on mortality (RR 99%, with confidence limits of 91-107%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b05e42f2-b39a-4d34-8d57-3a6e27c612e3"></a><a name="section-13.2"></a><p></p>
<h2>14.2 <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Chronic Atrial Fibrillation</span></h2>
<p class="First">Digoxin has also been studied as a means of controlling the ventricular response to <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">chronic atrial fibrillation</span> in adults. Digoxin reduced the resting heart rate, but not the heart rate during exercise. </p>
<p>In 3 different randomized, double-blind trials that included a total of 315 adult patients, digoxin was compared to placebo for the conversion of recent-onset <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> to sinus rhythm. Conversion was equally likely, and equally rapid, in the digoxin and placebo groups. In a randomized 120-patient trial comparing digoxin, sotalol, and amiodarone, patients randomized to digoxin had the lowest incidence of conversion to sinus rhythm, and the least satisfactory rate control when conversion did not occur. </p>
<p>In at least one study, digoxin was studied as a means of delaying reversion to <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> in adult patients with frequent recurrence of this <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>. This was a randomized, double-blind, 43-patient crossover study. Digoxin increased the mean time between symptomatic recurrent episodes by 54%, but had no effect on the frequency of fibrillatory episodes seen during continuous electrocardiographic monitoring. </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_922642ee-859e-4bae-964b-c03bd6d0ccdd"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Bold">LANOXIN Tablets have â€œLANOXINâ€? on one side and are supplied as follows:</span></p>
<table width="100%">
<col width="9%">
<col width="10%">
<col width="11%">
<col width="13%">
<col width="18%">
<col width="18%">
<col width="18%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Mcg</span></p></td>
<td class="Botrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Scored</span></p></td>
<td class="Botrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Color</span></p></td>
<td class="Botrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Imprint</span></p></td>
<td class="Toprule" align="center" colspan="3" valign="bottom"><p class="First"><span class="Bold">NDC 24987-xxx-xx</span></p></td>
</tr>
<tr>
<td class="Botrule" align="center" valign="bottom"><p class="First"><span class="Bold">Bottle/100</span></p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First"><span class="Bold">Bottle/1000</span></p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First"><span class="Bold">Unit dose/100</span></p></td>
</tr>
<tr>
<td class="Botrule" align="center" valign="middle"><p class="First">62.5</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">No</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">Peach</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">U3A</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">240-55</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">240-75</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">Not applicable</p></td>
</tr>
<tr>
<td class="Botrule" align="center" valign="middle"><p class="First">125</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">Yes</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">Yellow</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">Y3B</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">242-55<br>242-57</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">242-75<br>242-76</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">242-56</p></td>
</tr>
<tr>
<td class="Botrule" align="center" valign="middle"><p class="First">187.5</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">No</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">Blue</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">F3F</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">245-55</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">245-75</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">Not applicable</p></td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="middle"><p class="First">250</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">Yes</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">White</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">X3A</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">249-55<br>249-57</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">249-75<br>249-76</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">249-56</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Store at 25Â°C (77Â°F); excursions permitted to 15 to 30Â°C (59 to 86Â°F) in a dry place and protect from light. Keep out of reach of children.</span></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_1fffdf62-8056-4e1e-bdbc-2e6db772e4b5"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<dl>
<dt>â€¢</dt>
<dd>Advise patients that digoxin is a cardiac glycoside used to treat <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and heart <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>. </dd>
<dt>â€¢</dt>
<dd>Instruct patients to take this medication as directed by their physician. </dd>
<dt>â€¢</dt>
<dd>Advise patients that many drugs can interact with LANOXIN. Instruct patients to inform their doctor and pharmacist if they are taking any over the counter medications, including herbal medication, or are started on a new prescription. </dd>
<dt>â€¢</dt>
<dd>Advise patient that blood tests will be necessary to ensure that their LANOXIN dose is appropriate for them. </dd>
<dt>â€¢</dt>
<dd>Advise patients to contact their doctor or a health care professional if they experience <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, persistent <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, or <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> (including <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, green-yellow color disturbances, halo effect) as these could be signs that the dose of LANOXIN may be too high. </dd>
<dt>â€¢</dt>
<dd>Advise parents or caregivers that the symptoms of having too high LANOXIN doses may be difficult to recognize in infants and pediatric patients. Symptoms such as <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="437986" conceptname="Failure to thrive">failure to thrive</span> in infants, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and behavioral disturbances may be indications of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span>. </dd>
<dt>â€¢</dt>
<dd>Suggest to the patient to monitor and record their heart rate and blood pressure daily. </dd>
<dt>â€¢</dt>
<dd>Instruct women of childbearing potential who become or are planning to become pregnant to consult a physician prior to initiation or continuing therapy with LANOXIN.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_722a1169-fbb9-4a48-a58a-1656c8834e46"></a><a name="section-16"></a><p></p>
<p class="First">LANOXIN is a registered trademark of GlaxoSmithKline</p>
<p>COVIS</p>
<p>Distributed By<br>Covis Pharmaceuticals, Inc.<br>Cary, NC 27511</p>
<p>Manufactured by DSM Pharmaceuticals, Inc.<br>Greenville, NC 27834</p>
<p>Â©2013, Covis Pharmaceuticals, Inc. All rights reserved.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_e92ff305-d5e4-4d7e-b5a8-f1f46a29402c"></a><a name="section-17"></a><p></p>
<h1>Package/Label Display Panel </h1>
<p class="First">Lanoxin Tablets, USP</p>
<p>250 mcg (0.25 mg)</p>
<p>Digoxin</p>
<p>10 Tablets</p>
<div class="Figure">
<a name="id-1669855908"></a><img alt="bag label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0b96049b-e6b9-4ebb-bfe9-d5a73ed4f66b&amp;name=image-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LANOXINÂ 		
					</strong><br><span class="contentTableReg">digoxin tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-6726(NDC:24987-249)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DIGOXIN</strong> (DIGOXIN) </td>
<td class="formItem">DIGOXIN</td>
<td class="formItem">0.25Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">LANOXIN;X3A</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-6726-0</td>
<td class="formItem">10  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020405</td>
<td class="formItem">09/30/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Cardinal Health
							(188557102)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cardinal Health</td>
<td class="formItem"></td>
<td class="formItem">188557102</td>
<td class="formItem">REPACK(55154-6726)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>88241740-b8d9-40ea-b2fd-5fb6279af0dd</div>
<div>Set id: 0b96049b-e6b9-4ebb-bfe9-d5a73ed4f66b</div>
<div>Version: 3</div>
<div>Effective Time: 20140929</div>
</div>
</div>Â <div class="DistributorName">Cardinal Health</div></p>
</body></html>
